These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28548075)

  • 21. HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.
    Gaudino G; Yang H; Carbone M
    Biomedicines; 2014 Nov; 2(4):327-344. PubMed ID: 28548074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation.
    Owusu BY; Thomas S; Venukadasula P; Han Z; Janetka JW; Galemmo RA; Klampfer L
    Oncotarget; 2017 Sep; 8(38):63014-63025. PubMed ID: 28968967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promise and challenges on the horizon of MET-targeted cancer therapeutics.
    Zhang YW
    World J Biol Chem; 2015 May; 6(2):16-27. PubMed ID: 26009700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
    Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
    Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis.
    Liang H; Wang M
    Onco Targets Ther; 2020; 13():2491-2510. PubMed ID: 32273721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications.
    Zorzetto M; Ferrari S; Saracino L; Inghilleri S; Stella GM
    Transl Lung Cancer Res; 2012 Sep; 1(3):194-207. PubMed ID: 25806181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
    Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
    Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.
    Bonine-Summers AR; Aakre ME; Brown KA; Arteaga CL; Pietenpol JA; Moses HL; Cheng N
    Cancer Biol Ther; 2007 Apr; 6(4):561-70. PubMed ID: 17495520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
    Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M
    J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.
    Caenepeel S; Cooke K; Wadsworth S; Huang G; Robert L; Moreno BH; Parisi G; Cajulis E; Kendall R; Beltran P; Ribas A; Coxon A; Hughes PE
    Oncotarget; 2017 Mar; 8(11):17795-17809. PubMed ID: 28147313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.
    Owusu BY; Galemmo R; Janetka J; Klampfer L
    Cancers (Basel); 2017 Apr; 9(4):. PubMed ID: 28420162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
    Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
    J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling.
    Cecchi F; Rex K; Schmidt J; Vocke CD; Lee YH; Burkett S; Baker D; Damore MA; Coxon A; Burgess TL; Bottaro DP
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.
    Gusenbauer S; Vlaicu P; Ullrich A
    Oncogene; 2013 Aug; 32(33):3846-56. PubMed ID: 23045285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Huang WC; Yadav VK; Cheng WH; Wang CH; Hsieh MS; Huang TY; Lin SF; Yeh CT; Kuo KT
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
    Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
    Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    Zhao Y; Wang H; He C
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer.
    Sylvester PW
    Clin Transl Med; 2014 Dec; 3(1):30. PubMed ID: 26932375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.